DOI: 10.1128/iai.00208-26 ISSN: 0019-9567
Transcriptional analyses of peripheral blood lymphocytes obtained shortly after primary immunization discriminate vaccines against
Francisella tularensis
Roberto De Pascalis, Scott Espich, Hamda Khan, Mykia Toney, Chou Chao-Kai, Wu Wells, Karen L. Elkins ABSTRACT
The high virulence and pathogenesis of
Francisella tularensis
(
Ft
), responsible for tularemia, made it a target for bioweapon development during the “Cold War.” This prompted investigation of vaccines, starting with an older vaccine candidate denoted
Ft
live vaccine strain (LVS). LVS has limited efficacy against aerosol challenge with
Ft
subsp. Tularensis (Type A), the most virulent subtype. However, no vaccines, including LVS, have been licensed in the U.S. Animal studies indicate that
Ft
vaccines induce protective T-cell-mediated immune responses. In previous studies, analyses of leukocytes from vaccinated animals that were restimulated
in vitro
facilitated screening and selection of vaccines for more extensive
in vivo
evaluation. These studies demonstrated that a novel live attenuated vaccine strain derived from Type A
Ft
, denoted
ΔclpB
, was protective against aerosol challenge in animal models. In this study, we focused on evaluating immune responses immediately after vaccination of Fischer 344 rats with LVS and
ΔclpB
using multiple analytical approaches. While humoral immune responses were comparable between the two vaccines, we identified multiple differences in immune responses by analyses of peripheral blood leukocytes by flow cytometry and by relative gene expression. In particular, vaccination with LVS or
ΔclpB
resulted in differential expression of multiple genes at selected time points. Gene expression, in turn, predicted activation or inhibition of multiple biological pathways. These results suggest that immune responses shortly after primary vaccination may discriminate vaccines with different degrees of
in vivo
protection that could potentially be used as correlates of protection and extrapolate efficacy from animals to people.